Cargando…
Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD)
BACKGROUND: Diverse research approaches support the concept that a clinical diagnosis of Late-Onset Alzheimer's Disease (LOAD) does not distinguish between subpopulations with differing neuropathologies, including dementia patients with amyloid deposition and dementia patients without amyloid d...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802395/ https://www.ncbi.nlm.nih.gov/pubmed/27051586 http://dx.doi.org/10.1016/j.bbacli.2015.11.004 |
_version_ | 1782422711433166848 |
---|---|
author | Wood, Paul L. Locke, Victoria A. Herling, Patrick Passaro, Angelina Vigna, Giovanni B. Volpato, Stefano Valacchi, Giuseppe Cervellati, Carlo Zuliani, Giovanni |
author_facet | Wood, Paul L. Locke, Victoria A. Herling, Patrick Passaro, Angelina Vigna, Giovanni B. Volpato, Stefano Valacchi, Giuseppe Cervellati, Carlo Zuliani, Giovanni |
author_sort | Wood, Paul L. |
collection | PubMed |
description | BACKGROUND: Diverse research approaches support the concept that a clinical diagnosis of Late-Onset Alzheimer's Disease (LOAD) does not distinguish between subpopulations with differing neuropathologies, including dementia patients with amyloid deposition and dementia patients without amyloid deposition but with cortical thinning. Mild cognitive impairment (MCI) is generally considered the prodromal phase for LOAD, however, while a number of studies have attempted to define plasma biomarkers for the conversion of MCI to LOAD, these studies have not taken into account the heterogeneity of patient cohorts within a clinical phenotype. METHODS: Studies of MCI and LOAD in several laboratories have demonstrated decrements in ethanolamine plasmalogen levels in plasma and brain and increased levels of diacylglycerols in plasma and brain. To further extend these studies and to address the issue of heterogeneity in MCI and LOAD patient groups we investigated the levels of diacylglycerols and ethanolamine plasmalogens in larger cohorts of patients utilizing, high-resolution (0.2 to 2 ppm mass error) mass spectrometry. RESULTS: For the first time, our lipidomics data clearly stratify both MCI and LOAD subjects into 3 different patient cohorts within each clinical diagnosis. These include i) patients with lower circulating ethanolamine plasmalogen levels; ii) patients with augmented plasma diacylglycerol levels; and iii) patients with neither of these lipid alterations. CONCLUSIONS: These represent the first serum biochemical data to stratify MCI and LOAD patients, advancing efforts to biochemically define patient heterogeneity in cognitive disorders. GENERAL SIGNIFICANCE: Lipidomics offers a new approach for identifying biomarkers and biological targets in cognitive disorders. |
format | Online Article Text |
id | pubmed-4802395 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-48023952016-04-05 Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD) Wood, Paul L. Locke, Victoria A. Herling, Patrick Passaro, Angelina Vigna, Giovanni B. Volpato, Stefano Valacchi, Giuseppe Cervellati, Carlo Zuliani, Giovanni BBA Clin Regular Article BACKGROUND: Diverse research approaches support the concept that a clinical diagnosis of Late-Onset Alzheimer's Disease (LOAD) does not distinguish between subpopulations with differing neuropathologies, including dementia patients with amyloid deposition and dementia patients without amyloid deposition but with cortical thinning. Mild cognitive impairment (MCI) is generally considered the prodromal phase for LOAD, however, while a number of studies have attempted to define plasma biomarkers for the conversion of MCI to LOAD, these studies have not taken into account the heterogeneity of patient cohorts within a clinical phenotype. METHODS: Studies of MCI and LOAD in several laboratories have demonstrated decrements in ethanolamine plasmalogen levels in plasma and brain and increased levels of diacylglycerols in plasma and brain. To further extend these studies and to address the issue of heterogeneity in MCI and LOAD patient groups we investigated the levels of diacylglycerols and ethanolamine plasmalogens in larger cohorts of patients utilizing, high-resolution (0.2 to 2 ppm mass error) mass spectrometry. RESULTS: For the first time, our lipidomics data clearly stratify both MCI and LOAD subjects into 3 different patient cohorts within each clinical diagnosis. These include i) patients with lower circulating ethanolamine plasmalogen levels; ii) patients with augmented plasma diacylglycerol levels; and iii) patients with neither of these lipid alterations. CONCLUSIONS: These represent the first serum biochemical data to stratify MCI and LOAD patients, advancing efforts to biochemically define patient heterogeneity in cognitive disorders. GENERAL SIGNIFICANCE: Lipidomics offers a new approach for identifying biomarkers and biological targets in cognitive disorders. Elsevier 2015-11-14 /pmc/articles/PMC4802395/ /pubmed/27051586 http://dx.doi.org/10.1016/j.bbacli.2015.11.004 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Regular Article Wood, Paul L. Locke, Victoria A. Herling, Patrick Passaro, Angelina Vigna, Giovanni B. Volpato, Stefano Valacchi, Giuseppe Cervellati, Carlo Zuliani, Giovanni Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD) |
title | Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD) |
title_full | Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD) |
title_fullStr | Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD) |
title_full_unstemmed | Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD) |
title_short | Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD) |
title_sort | targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (mci) and late onset alzheimer's disease (load) |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802395/ https://www.ncbi.nlm.nih.gov/pubmed/27051586 http://dx.doi.org/10.1016/j.bbacli.2015.11.004 |
work_keys_str_mv | AT woodpaull targetedlipidomicsdistinguishespatientsubgroupsinmildcognitiveimpairmentmciandlateonsetalzheimersdiseaseload AT lockevictoriaa targetedlipidomicsdistinguishespatientsubgroupsinmildcognitiveimpairmentmciandlateonsetalzheimersdiseaseload AT herlingpatrick targetedlipidomicsdistinguishespatientsubgroupsinmildcognitiveimpairmentmciandlateonsetalzheimersdiseaseload AT passaroangelina targetedlipidomicsdistinguishespatientsubgroupsinmildcognitiveimpairmentmciandlateonsetalzheimersdiseaseload AT vignagiovannib targetedlipidomicsdistinguishespatientsubgroupsinmildcognitiveimpairmentmciandlateonsetalzheimersdiseaseload AT volpatostefano targetedlipidomicsdistinguishespatientsubgroupsinmildcognitiveimpairmentmciandlateonsetalzheimersdiseaseload AT valacchigiuseppe targetedlipidomicsdistinguishespatientsubgroupsinmildcognitiveimpairmentmciandlateonsetalzheimersdiseaseload AT cervellaticarlo targetedlipidomicsdistinguishespatientsubgroupsinmildcognitiveimpairmentmciandlateonsetalzheimersdiseaseload AT zulianigiovanni targetedlipidomicsdistinguishespatientsubgroupsinmildcognitiveimpairmentmciandlateonsetalzheimersdiseaseload |